The lack of significant differences in CD58 expression between treated ALL groups and controls, as well as between ALL and CLL groups when considering all treated ALL cases together, might reflect patient heterogeneity or the dynamic nature of CD58 regulation in response to chemotherapy. This evidence concerns the gene CD58 and B-cell chronic lymphocytic leukemia.